6NQ Stock Overview
A pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Synthaverse S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł0.93 |
52 Week High | zł1.28 |
52 Week Low | zł0.63 |
Beta | 1.13 |
11 Month Change | -1.91% |
3 Month Change | -14.67% |
1 Year Change | -4.98% |
33 Year Change | -51.24% |
5 Year Change | n/a |
Change since IPO | -78.98% |
Recent News & Updates
Recent updates
Shareholder Returns
6NQ | DE Biotechs | DE Market | |
---|---|---|---|
7D | -1.2% | -0.4% | -1.8% |
1Y | -5.0% | -14.9% | 13.2% |
Return vs Industry: 6NQ exceeded the German Biotechs industry which returned -15.2% over the past year.
Return vs Market: 6NQ underperformed the German Market which returned 16.1% over the past year.
Price Volatility
6NQ volatility | |
---|---|
6NQ Average Weekly Movement | 4.3% |
Biotechs Industry Average Movement | 6.4% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6NQ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6NQ's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1944 | 239 | Mieczyslaw Starkowicz | www.synthaverse.pl |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.
Synthaverse S.A. Fundamentals Summary
6NQ fundamental statistics | |
---|---|
Market cap | €69.75m |
Earnings (TTM) | €566.92k |
Revenue (TTM) | €13.15m |
123.0x
P/E Ratio5.3x
P/S RatioIs 6NQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6NQ income statement (TTM) | |
---|---|
Revenue | zł57.35m |
Cost of Revenue | zł22.61m |
Gross Profit | zł34.74m |
Other Expenses | zł32.27m |
Earnings | zł2.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 20, 2024
Earnings per share (EPS) | 0.035 |
Gross Margin | 60.57% |
Net Profit Margin | 4.31% |
Debt/Equity Ratio | 69.4% |
How did 6NQ perform over the long term?
See historical performance and comparison